Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKAB2 | O43741 | 6/20 | 0.33 |
| ▸ | PRKAG1 | P54619 | 6/20 | 0.33 |
| ▸ | PRKAA2 | P54646 | 6/20 | 0.33 |
| ▸ | PRKAA1 | Q13131 | 6/20 | 0.33 |
| ▸ | PRKAG3 | Q9UGI9 | 6/20 | 0.33 |
| ▸ | PRKAG2 | Q9UGJ0 | 6/20 | 0.33 |
| ▸ | PRKAB1 | Q9Y478 | 6/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.30 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL35211555 | 1.00 | PRKAB2 (0.33) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31342230 | 1.00 | PRKAB2 (0.33) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL31341963 | 0.93 | DHODH (0.33) | PRKAB2PRKAG1PRKAA2PRKAA1PRKAG3 | |
| SCHEMBL35211913 | 0.91 | CYP4A11 (0.35) | DHODH | |
| SCHEMBL35211571 | 0.91 | CYP4A11 (0.35) | DHODH | |
| SCHEMBL35211910 | 0.91 | CYP4A11 (0.35) | DHODH | |
| SCHEMBL35212168 | 0.85 | TTR (0.31) | RARARARB | |
| SCHEMBL31342430 | 0.84 | CYP4A11 (0.39) | DHODH | |
| SCHEMBL35212228 | 0.82 | AR (0.34) | — | |
| SCHEMBL30879998 | 0.79 | AKR1C3 (0.38) | DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| WO-2025049820-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2025-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | PRKAB2 2436/4885PRKAG1 3458/4885PRKAA2 2363/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.